Morphic Medical

Morphic Medical is a Boston-based medical technology company founded in 2003. The company focuses on developing innovative treatments for type 2 diabetes and obesity, aiming to provide alternatives for patients who are underserved by traditional pharmaceutical therapies and may not be candidates for surgery. The flagship product, RESET®, is the first endoscopically delivered device therapy designed specifically for these conditions. This duodenal jejunal bypass liner (DJBL) technology is implanted endoscopically to help reduce hemoglobin A1c (HbA1c) levels and promote weight loss, offering a less invasive option compared to bariatric surgery. Morphic Medical is actively conducting clinical research, including the STEP-1 clinical study in the United States, to evaluate the safety and efficacy of RESET®. The company has also achieved regulatory milestones, such as obtaining the CE Mark for commercialization in Europe. Morphic Medical's leadership team consists of experienced professionals in medical devices and finance, committed to advancing healthcare technologies to improve patient outcomes in diabetes and obesity.

• Employees 50
• Founded 2003
• Total Funding $11600000